Please login to the form below

Not currently logged in
Email:
Password:

FDA advises against BMS/AZ diabetes drug

An advisory committee to the US Food and Drug Administration has recommended against the marketing approval for dapagliflozin, a diabetes drug developed by AstraZeneca and Bristol-Myers Squibb

An advisory committee to the US Food and Drug Administration  (FDA) has recommended against the marketing approval for dapagliflozin, a diabetes drug developed by AstraZeneca (AZ) and Bristol-Myers Squibb (BMS).

The Endocrinologic and Metabolic Drugs Advisory Committee  voted nine to six in opposition to a question regarding whether evidence about the drug's safety and efficacy supported its use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Both companies said they remained committed to the development of dapagliflozin, and will work with the FDA in its review of the drug.

The FDA does not have to follow the Committee's recommendation, but it frequently does so, and will take the advice into consideration when reviewing the marketing application.

Dapagliflozin is potentially the first in a new class of insulin-independent, oral type 2 diabetes agent. It is developed as an inhibitor of SGLT2, a 'glucose cotransporter' in the kidney that plays a role in the reabsorption of glucose into the blood.

20th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics